

Koichi Miyamura M.D. Ph.D.

Present position

Director Assistant

Director Hematopoietic Cell Transplantation Center

Head, Department of Hematology

Japanese Red Cross Nagoya First Hospital

Education and Experience

1983.3 Graduation and MD from Nagoya University School of Medicine

1983.4-1988.3 Internship and Residency, Japanese Red Cross Nagoya First Hospital

1988.4-1989.6 Clinical Fellow, Department of Chemotherapy Tokyo Metropolitan Komagome Hospital

1989.7-1992.3 Research Fellow, First Department of Internal Medicine Nagoya University School of Medicine

1992.3 PhD from Nagoya University School of Medicine

1992.4-1994.6 Visiting Associate, Department of Hematology, NHLBI National Institute of Health, Bethesda, USA

1994.7-2000.3 Clinical Fellow, First Department of Internal Medicine Nagoya University School of Medicine

2000.4-2002.3 Assistant Professor, Department of Hematology/ Immunology Tohoku University School of Medicine

2002.4-2003.3 Lecture, Department of Hematology/ Immunology Tohoku University School of Medicine

2003.4-2003.6 Associate Professor, Department of Hematology/ Immunology Tohoku University School of Medicine

2005.7-Present Head, Department of Hematology Japanese Red Cross Nagoya First Hospital

2008.4-Present Director, Hematopoietic Cell Transplantation Center, Japanese Red Cross Nagoya First Hospital

2013.4-2016.12 Deputy Director, Japanese Red Cross Nagoya First Hospital

2017.1 Director Assistant, Japanese Red Cross Nagoya First Hospital

Board Certification

Fellowship, Japanese Society of Internal medicine

Membership, Japanese Society of Internal medicine

Membership, Japanese Society of Hematology

Japanese Society of hematopoietic Cell Transplantation

Membership of Academic Society:

Board of Directors, Japan Society of Hematopoietic Cell Transplantation

Scientific Committee, Asia-Pacific Blood and Marrow Transplantation

Trustee, Japan Hematological Society

Publications

1. Yamauchi T, Miyamura K, Nomura S, Minami S, Yoshikawa H, Sakai S, Yoshikawa S, Kodera Y, Sao H, Tahara T, et al. [Interstitial pneumonia in leukemia patients after allogeneic bone marrow transplantation]. *Rinsho Ketsueki* 1986; **27**: 1361-8.
2. Miyamura K, Minami S, Matsuyama T, Kodera Y, Yamauchi T, Tahara T, Sao H, Morishima Y, Yokomaku S. Adenovirus-induced late onset hemorrhagic cystitis following allogeneic bone marrow transplantation. *Bone Marrow Transplant* 1987; **2**: 109-10.
3. Sao H, Sobue R, Miyamura K, Kodera Y, Morishima Y, Kurachi T, Okada K, Kato O, Takamatsu Y, Kuramoto A, et al. [Successful bone marrow transplantation in a case of severe aplastic anemia refractory to platelet transfusions]. *Rinsho Ketsueki* 1987; **28**: 2146-52.
4. Sobue R, Yamauchi T, Miyamura K, Sao H, Tahara T, Yoshikawa H, Yoshikawa S, Morishima Y, Kodera Y. Treatment of adult T cell leukemia with mega-dose cyclophosphamide and total body irradiation followed by allogeneic bone marrow transplantation. *Bone Marrow Transplant* 1987; **2**: 441-4.
5. Kojima S, Fukuda M, Horibe K, Matsuyama K, Miyamura K, Kodera Y. [Antilymphocyte globulin treatment in children with aplastic anemia]. *Rinsho Ketsueki* 1988; **29**: 676-81.
6. Kojima S, Fukuda M, Horibe K, Matsuyama K, Takeyama K, Matsushita T,

- Miyamura K, Kimura Y, Minami S, Kodera Y. Comparison between bone marrow transplantation and immuno-suppressive therapy in treatment of patients younger than 20 years with severe aplastic anemia. *Nihon Ketsueki Gakkai Zasshi* 1988; **51**: 28-35.
7. Miyamura K, Kojima S, Takeyama K, Matsushita T, Fukuda M, Horibe K, Minami S, Morishima Y, Matsuyama K, Kodera Y. Use of cyclophosphamide and total lymphoid irradiation combined with cyclosporine in bone marrow transplantation for transfused severe aplastic anemia. *Bone Marrow Transplant* 1988; **3**: 457-61.
 8. Miyamura K, Takeyama K, Matsushita T, Kimura M, Minami S, Yoshida J, Matsuyama K, Kodera Y, Yamauchi T, Hiraiwa A, et al. [Allogeneic bone marrow transplantation for Burkitt's lymphoma (stage IV)]. *Rinsho Ketsueki* 1988; **29**: 149-55.
 9. Kojima S, Fukuda M, Horibe K, Matsuyama T, Takeyama K, Matsushita T, Miyamura K, Sugihara T, Minami S, Kodera Y. [Prolonged thrombocytopenia after autologous bone marrow transplantation]. *Rinsho Ketsueki* 1989; **30**: 175-80.
 10. Kojima S, Matsuyama K, Miyamura K, Kodera Y. Aplastic anemia: lack of increase of in vitro colony formation after T cell depletion with monoclonal antibodies and complement. *Nihon Ketsueki Gakkai Zasshi* 1989; **52**: 965-71.
 11. Matsushita T, Akatsuka Y, Towatari M, Takeyama K, Miyamura K, Sugihara T, Minami S, Kodera Y. [Cyclosporine as prophylaxis for graft versus host disease in adults undergoing allogeneic bone marrow transplantation]. *Rinsho Ketsueki* 1989; **30**: 429-36.
 12. Miyamura K, Kojima S, Takeyama K, Matsushita T, Minami S, Kodera Y. [Severe aplastic anemia remarkably improved by a treatment with antilymphocyte globulin, high-dose methylprednisolone and danazol]. *Rinsho Ketsueki* 1989; **30**: 72-7.
 13. Miyamura K, Takeyama K, Kojima S, Minami S, Matsuyama K, Morishima Y, Kodera Y. Hemorrhagic cystitis associated with urinary excretion of adenovirus type 11 following allogeneic bone marrow transplantation. *Bone Marrow Transplant* 1989; **4**: 533-5.
 14. Miyamura K, Imai K, Mizutani S. [Application of polymerase chain reaction for bone

- marrow transplantation]. *Rinsho Ketsueki* 1990; **31**: 597-602.
15. Miyamura K, Morishima Y, Tanimoto M, Saito H, Kojima S, Kodera Y, Mizutani S. Prediction of clinical relapse after bone-marrow transplantation by PCR for Philadelphia-positive acute lymphoblastic leukaemia. *Lancet* 1990; **336**: 890.
 16. Miyamura K, Osada H, Yamauchi T, Itoh M, Kodera Y, Suchi T, Takahashi T, Ueda R. Single clonal origin of neoplastic B-cells with different immunoglobulin light chains in a patient with Richter's syndrome. *Cancer* 1990; **66**: 140-4.
 17. Kataoka T, Miyamura K. [Autologous bone marrow transplantation for acute leukemia]. *Rinsho Ketsueki* 1991; **32**: 381-5.
 18. Miyamura K, Kobayashi T, Sasaki T, Ibuka T, Imai K, Sakai Y, Kawaguchi K, Miyashita T, Iwaya M, Mizutani S. Gene amplification of Japanese non-Hodgkin lymphoma with involvement of the BCL2 gene. *Int J Hematol* 1991; **54**: 137-40.
 19. Miyamura K, Morishima Y. [Bone marrow transplantation]. *Rinsho Byori* 1991; **Suppl 90**: 23-34.
 20. Takeuchi K, Nisimura S, Furuta H, Satogami E, Ekawa K, Sanke T, Kondo M, Nanjyo K, Miyamura K, Morikawa Y, et al. [A case of so-called neoplastic angioendotheliosis with fever of unknown origin and temporary loss of consciousness]. *Rinsho Ketsueki* 1991; **32**: 127-31.
 21. Yazaki M, Miyamura K, Kojima S, Kodera Y, Hirabayashi N, Horibe K, Morishima Y, Wada Y. [Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia]. *Rinsho Ketsueki* 1991; **32**: 851-4.
 22. Akatsuka Y, Kodera Y, Yamamoto K, Minami S, Miyamura K, Morishita Y, Morishima Y, Saitoh H, Horibe K, Yamauchi T. Bone marrow transplantation for chronic myelogenous leukemia in blastic phase using a phenotypically identical unrelated volunteer donor. Nagoya Bone Marrow Transplantation Group (NBMTG), Tokai Marrow Donor Bank (TMDB). *Int J Hematol* 1992; **55**: 249-53.
 23. Kiyoi H, Miyamura K. [Detection of MRD using BCR/ABL and immunoglobulin gene]. *Rinsho Ketsueki* 1992; **33**: 924-8.

24. Miyamura K, Tanimoto M, Morishima Y, Horibe K, Yamamoto K, Akatsuka M, Kodera Y, Kojima S, Matsuyama K, Hirabayashi N, et al. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation. *Blood* 1992; **79**: 1366-70.
25. Matsuoka A, Miyamura K, Emi N, Tahara T, Tanimoto M, Naoe T, Ohno R, Kakizuka A, Evans RM, Saito H. Unexpected heterogeneity of PML/RAR alpha fused mRNA detected by nested polymerase chain reaction in acute promyelocytic leukemia. *Leukemia* 1993; **7**: 1151-5.
26. Miyamura K, Tahara T, Tanimoto M, Morishita Y, Kawashima K, Morishima Y, Saito H, Tsuzuki S, Takeyama K, Kodera Y, et al. Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients. *Blood* 1993; **81**: 1089-93.
27. Miyamura K, Takeo T, Kataoka T, Tahara T, Tanimoto M, Saito H. Detection of minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia: rationale for bone marrow transplantation from the polymerase chain reaction point of view. *Leuk Lymphoma* 1993; **11**: 181-9.
28. Morishima Y, Miyamura K, Kojima S, Ueda R, Morishita Y, Sao H, Tanimoto M, Ohno R, Sobue R, Hirano M, et al. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement. *Bone Marrow Transplant* 1993; **11**: 255-9.
29. Ito Y, Miyamura K. Clinical significance of minimal residual disease in leukemia detected by polymerase chain reaction: is molecular remission a milestone for achieving a cure? *Leuk Lymphoma* 1994; **16**: 57-64.
30. Miyamura K, Barrett AJ, Kodera Y, Saito H. Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: a review of recent results. *Bone Marrow Transplant* 1994; **14**: 201-9.
31. Miyamura K, Kajigaya S, Momoeda M, Smith-Gill SJ, Young NS. Parvovirus

- particles as platforms for protein presentation. *Proc Natl Acad Sci U S A* 1994; **91**: 8507-11.
32. Miyamura K, Malhotra R, Hoppe HJ, Reid KB, Phizackerley PJ, Macpherson P, Lopez Bernal A. Surfactant proteins A (SP-A) and D (SP-D): levels in human amniotic fluid and localization in the fetal membranes. *Biochim Biophys Acta* 1994; **1210**: 303-7.
 33. Momoeda M, Kawase M, Jane SM, Miyamura K, Young NS, Kajigaya S. The transcriptional regulator YY1 binds to the 5'-terminal region of B19 parvovirus and regulates P6 promoter activity. *J Virol* 1994; **68**: 7159-68.
 34. Miyamura K, Sadahiro S, Konda T, Takahashi M, Fujino R, Nishimura Y, Miyakoshi H, Horiuchi K, Furuya Y, Kubota T, et al. Development and usefulness of the gelatin-particle-agglutination test for titration of antibodies against diphtheria, pertussis and tetanus toxins. *Jpn J Med Sci Biol* 1995; **48**: 49-59.
 35. Okada H, Miyamura K, Itoh T, Hagiwara M, Wakabayashi T, Mizuno M, Colosi P, Kurtzman G, Yoshida J. Gene therapy against an experimental glioma using adeno-associated virus vectors. *Gene Ther* 1996; **3**: 957-64.
 36. Iijima N, Miyamura K, Itou T, Tanimoto M, Sobue R, Saito H. Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: possible correlation with sensitivity to chemotherapy. *Blood* 1997; **90**: 4901-9.
 37. Towatari M, Miyamura K, Akatsuka Y, Yamamoto K, Minami S, Kodera Y. Prolonged selective neutropenia after allogeneic bone marrow transplantation: possible effect of presensitization by donor lymphocytes prior to transplant. *Int J Hematol* 1997; **66**: 513-6.
 38. Itou T, Miyamura K, Abe A, Emi N, Tanimoto M, Terasaki H, Shimadzu M, Saito H. Recombinant adeno-associated virus-mediated gene transfer into human leukemia cell lines. *Int J Hematol* 1998; **67**: 27-35.
 39. Mizuta S, Ito Y, Kohno A, Kiyoi H, Miyamura K, Tanimoto M, Takamatsu J, Naoe T, Morishima Y, Ueda R, Saito H. Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common

- ALL treated by autologous bone marrow transplantation. Nagoya BMT Group. *Bone Marrow Transplant* 1999; **24**: 777-84.
40. Miyamura K, Hamaguchi M, Taji H, Kanie T, Kohno A, Tanimoto M, Saito H, Kojima S, Matsuyama T, Kitaori K, Nagafuji K, Sato T, Kodera Y. Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors. *Bone Marrow Transplant* 2000; **25**: 545-8.
 41. Yokozawa T, Miyamura K, Fujino R, Yonehara S, Ueda R, Tanimoto M, Saito H. Gelatin beads as platforms for targeting molecule and anti-Fas antibody: two major properties of cytotoxic T lymphocytes. *Exp Hematol* 2000; **28**: 1129-36.
 42. Kohno A, Tsuzuki S, Kasai M, Miyamura K, Emi N, Tanimoto M, Saito H. Acute promyelocytic leukemia with apparently normal karyotype: molecular findings and response to all-trans retinoic acid. *Leuk Lymphoma* 2001; **42**: 151-61.
 43. Harigae H, Ichinohasama R, Miura I, Kameoka J, Meguro K, Miyamura K, Sasaki O, Ishikawa I, Takahashi S, Kaku M, Sasaki T. Primary marginal zone lymphoma of the thymus accompanied by chromosomal anomaly 46,X,dup(X)(p11p22). *Cancer Genet Cytogenet* 2002; **133**: 142-7.
 44. Abe S, Miyamura K, Oba T, Terakura S, Kasai M, Kitaori K, Sasaki T, Kodera Y. Oral ribavirin for severe adenovirus infection after allogeneic marrow transplantation. *Bone Marrow Transplant* 2003; **32**: 1107-8.
 45. Ine S, Yamada M, Miyamura K, Sasaki T. [Immunological mechanisms of graft versus tumor effect]. *Nihon Rinsho* 2003; **61**: 1495-502.
 46. Yokoyama H, Harigae H, Takahashi S, Kameoka J, Miyamura K, Ishizawa K, Kaku M, Sasaki T. High expression of YB-1 gene in erythroid cells in patients with refractory anemia. *Int J Hematol* 2003; **78**: 213-8.
 47. Okuda M, Nomura J, Horiuchi T, Miyamura K, Sasaki T. [Non-myeloablative stem cell transplantation from an HLA identical sibling donor in a case of treatment-related acute myelogenous leukemia]. *Rinsho Ketsueki* 2004; **45**: 308-11.
 48. Satoh M, Miyamura K, Yamada M, Ishidoya S, Childs RW, Arai Y. Haploidentical,

non-myeloablative stem-cell transplantation for advanced renal-cell carcinoma. *Lancet Oncol* 2004; **5**: 125-6.

49. Yamada M, Miyamura K, Fujiwara T, Yokoyama H, Tomiya Y, Ishizawa K, Harigae H, Kameoka J, Sasaki T. Imatinib mesylate in conjunction with allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome positive leukemias: report of 4 cases. *Tohoku J Exp Med* 2004; **204**: 79-84.
50. Inamoto Y, Teramoto T, Shirai K, Tsukamoto H, Sanda T, Miyamura K, Yamamori I, Hirabayashi N, Kodera Y. Severe hypercholesterolemia associated with decreased hepatic triglyceride lipase activity and pseudohyponatremia in patients after allogeneic stem cell transplantation. *Int J Hematol* 2005; **82**: 362-6.
51. Ishikawa I, Miyamura K, Yamada M, Sasaki O, Harigae H, Kameoka J, Meguro K, Sasaki T. [Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia]. *Rinsho Ketsueki* 2005; **46**: 1288-92.
52. Onizuka M, Kasai M, Oba T, Atsuta Y, Terakura S, Suzuki R, Kitaori K, Miyamura K, Hotta T, Kodera Y. Increased frequency of the angiotensin-converting enzyme gene D-allele is associated with noninfectious pulmonary dysfunction following allogeneic stem cell transplant. *Bone Marrow Transplant* 2005; **36**: 617-20.
53. Inamoto Y, Kuwatsuka Y, Tsujimura A, Tokunaga M, Oba T, Miyamura K, Kodera Y. [Allogeneic stem cell transplantation with fludarabine/melphalan (non-TBI and non-BU/CY) for patients aged 50 or more]. *Rinsho Ketsueki* 2006; **47**: 9-15.
54. Inamoto Y, Oba T, Miyamura K, Terakura S, Tsujimura A, Kuwatsuka Y, Tokunaga M, Kasai M, Murata M, Naoe T, Kodera Y. Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor. *Int J Hematol* 2006; **83**: 356-62.
55. Ishikawa I, Kato C, Harigae H, Sugawara T, Tomiya Y, Yamada M, Ishizawa K, Kameoka J, Miyamura K, Sasaki T. Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia. *Tohoku J Exp Med* 2006; **210**: 355-63.
56. Kameoka J, Horiuchi T, Miyamura K, Miura I, Okuda M, Nomura J, Hirokawa M,

- Sawada K, Sasaki T. [Acute monoblastic leukemia with tetrasomy 8]. *Rinsho Ketsueki* 2006; **47**: 770-6.
57. Takami A, Shimadoi S, Sugimori C, Takemoto K, Shibayama M, Yoshida T, Murayama T, Nagai K, Miyamura K, Asakura H, Nakao S. Successful treatment of minimal residual disease-positive Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib followed by reduced-intensity unrelated cord blood transplantation after allogeneic peripheral blood stem cell transplantation. *Int J Hematol* 2006; **84**: 170-3.
58. Tsujimura A, Miyamura K, Kuwatsuka Y, Inamoto Y, Tokunaga M, Oba T, Terakura S, Suzuki R, Ito M, Murase T, Kodera Y. [Successful salvage therapy with cladribine and rituximab for a patient with a relapsed Asian variant of intravascular large B-cell lymphoma]. *Rinsho Ketsueki* 2006; **47**: 1387-92.
59. Inamoto Y, Kuwatsuka Y, Oba T, Terakura S, Sugimoto K, Tsujimura A, Takahashi T, Yasuda T, Miyamura K, Kodera Y. Serologically HLA-DR-mismatched unrelated donors might provide a valuable alternative in allogeneic transplantation: experience from a single Japanese institution. *Int J Hematol* 2007; **85**: 163-9.
60. Inamoto Y, Miyamura K. [Prognostic prediction in chronic leukemia]. *Nihon Rinsho* 2007; **65 Suppl 1**: 658-61.
61. Inamoto Y, Nishida T, Suzuki R, Miyamura K, Sao H, Iida H, Naoe T, Maruyama F, Hirabayashi N, Hamaguchi M, Iseki T, Kami M, Yano K, Takeyama H, Morishita Y, Morishima Y, Kodera Y. Significance of additional high-dose cytarabine in combination with cyclophosphamide plus total body irradiation regimen for allogeneic stem cell transplantation. *Bone Marrow Transplant* 2007; **39**: 25-30.
62. Kawase T, Akatsuka Y, Torikai H, Morishima S, Oka A, Tsujimura A, Miyazaki M, Tsujimura K, Miyamura K, Ogawa S, Inoko H, Morishima Y, Kodera Y, Kuzushima K, Takahashi T. Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. *Blood* 2007; **110**: 1055-63.
63. Mizuta S, Kohno A, Morishita Y, Atsuta Y, Sao H, Miyamura K, Sakamaki H, Ueda R, Morishima Y. Long-term follow-up of 14 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia following autologous bone marrow transplantation in first complete remission. *Int J Hematol* 2007; **85**: 140-5.

64. Narimatsu H, Terakura S, Matsuo K, Oba T, Uchida T, Iida H, Hamaguchi M, Watanabe M, Kohno A, Murata M, Sawa M, Miyamura K, Morishita Y. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults. *Bone Marrow Transplant* 2007; **39**: 31-9.
65. Oba T, Suzuki R, Miyamura K, Kodera Y. Huge mass of cutaneous-type adult T-cell leukemia which responded to interferon gamma. *Intern Med* 2007; **46**: 147.
66. Ozawa S, Nakaseko C, Nishimura M, Maruta A, Cho R, Ohwada C, Sakamaki H, Sao H, Mori S, Okamoto S, Miyamura K, Kato S, Kawase T, Morishima Y, Kodera Y. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. *Br J Haematol* 2007; **137**: 142-51.
67. Shimada M, Onizuka M, Machida S, Suzuki R, Kojima M, Miyamura K, Kodera Y, Inoko H, Ando K. Association of autoimmune disease-related gene polymorphisms with chronic graft-versus-host disease. *Br J Haematol* 2007; **139**: 458-63.
68. Tokunaga M, Miyamura K, Ohashi H, Ishiwada N, Terakura S, Ikeguchi M, Kuwatsuka Y, Inamoto Y, Oba T, Tsuchiya S, Kodera Y. Successful nonmyeloablative bone marrow transplantation for leukocyte adhesion deficiency type I from an unrelated donor. *Int J Hematol* 2007; **86**: 91-5.
69. Torikai H, Akatsuka Y, Miyauchi H, Terakura S, Onizuka M, Tsujimura K, Miyamura K, Morishima Y, Kodera Y, Kuzushima K, Takahashi T. The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206. *Bone Marrow Transplant* 2007; **40**: 165-74.
70. Usui N, Miyamura K, Arai A, Motomura S, Yokoyama M. [Physiopathology, diagnosis and treatment of chronic myeloproliferative diseases: discussion]. *Nihon Naika Gakkai Zasshi* 2007; **96**: 1434-55.
71. Abe S, Kameoka J, Fujiwara M, Harigae H, Sasaki O, Miyamura K. Trisomies 4 and 10 in acute myeloid leukemia: report of a new case. *Cancer Genet Cytogenet* 2008; **185**: 55-6.

72. Inamoto Y, Suzuki R, Kuwatsuka Y, Yasuda T, Takahashi T, Tsujimura A, Sugimoto K, Oba T, Terakura S, Atsuta Y, Murata M, Ito M, Koderu Y, Miyamura K. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen. *Biol Blood Marrow Transplant* 2008; **14**: 43-9.
73. Kawase T, Nannya Y, Torikai H, Yamamoto G, Onizuka M, Morishima S, Tsujimura K, Miyamura K, Koderu Y, Morishima Y, Takahashi T, Kuzushima K, Ogawa S, Akatsuka Y. Identification of human minor histocompatibility antigens based on genetic association with highly parallel genotyping of pooled DNA. *Blood* 2008; **111**: 3286-94.
74. Kimura F, Sato K, Kobayashi S, Ikeda T, Sao H, Okamoto S, Miyamura K, Mori S, Akiyama H, Hirokawa M, Ohto H, Ashida H, Motoyoshi K. Impact of ABO-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program. *Haematologica* 2008; **93**: 1686-93.
75. Kohno A, Morishita Y, Iida H, Yanada M, Uchida T, Hamaguchi M, Sawa M, Sugiura I, Yamamoto K, Mizuta S, Sao H, Naoe T, Miyamura K. Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group. *Int J Hematol* 2008; **87**: 210-6.
76. Nagamura-Inoue T, Kai S, Azuma H, Takanashi M, Isoyama K, Kato K, Takahashi S, Taniguchi S, Miyamura K, Aoki K, Hidaka M, Nagamura F, Tojo A, Fang X, Kato S. Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis. *Bone Marrow Transplant* 2008; **42**: 241-51.
77. Narimatsu H, Watanabe M, Kohno A, Sugimoto K, Kuwatsuka Y, Uchida T, Murata M, Miyamura K, Morishita Y. High incidence of graft failure in unrelated cord blood transplantation using a reduced-intensity preparative regimen consisting of fludarabine and melphalan. *Bone Marrow Transplant* 2008; **41**: 753-6.
78. Sugimoto K, Murata M, Onizuka M, Inamoto Y, Terakura S, Kuwatsuka Y, Oba T, Miyamura K, Koderu Y, Naoe T. Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the

- 5,10-methylenetetrahydrofolate reductase 677TT genotype. *Int J Hematol* 2008; **87**: 451-8.
79. Sugimoto K, Narimatsu H, Kawase T, Iida H, Watanabe M, Kohno A, Kuwatsuka Y, Uchida T, Hamaguchi M, Terakura S, Naoe T, Matsuo K, Murata M, Sawa M, Miyamura K, Morishita Y. Clinical characteristics of chronic graft-versus-host disease following umbilical cord blood transplantation for adults. *Bone Marrow Transplant* 2008; **41**: 729-36.
80. Yamada MF, Fujiwara T, Ishikawa I, Kohata K, Katoh C, Miyamura K, Harigae H. Interlaboratory comparison of quantitative RT-PCR based detection for minimal residual disease in leukemias: a standardization approach in Japan. *Tohoku J Exp Med* 2008; **214**: 97-104.
81. Yamada MF, Miyamura K, Fujiwara T, Kohata K, Okitsu Y, Ohguchi H, Yamamoto J, Yokoyama H, Tomiya Y, Ishizawa K, Kameoka J, Harigae H. Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis. *Transplant Proc* 2008; **40**: 3637-42.
82. Espinoza JL, Takami A, Onizuka M, Sao H, Akiyama H, Miyamura K, Okamoto S, Inoue M, Kanda Y, Ohtake S, Fukuda T, Morishima Y, Kodera Y, Nakao S. NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies. *Haematologica* 2009; **94**: 1427-34.
83. Imahashi N, Tokunaga M, Nishiwaki S, Yanagisawa M, Ozawa Y, Miyamura K. Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation. *Rinsho Ketsueki* 2009; **50**: 1612-5.
84. Inamoto Y, Ito M, Suzuki R, Nishida T, Iida H, Kohno A, Sawa M, Murata M, Nishiwaki S, Oba T, Yanada M, Naoe T, Ichihashi R, Fujino M, Yamaguchi T, Morishita Y, Hirabayashi N, Kodera Y, Miyamura K. Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. *Bone Marrow Transplant* 2009; **44**: 43-9.
85. Inamoto Y, Kurahashi S, Imahashi N, Fukushima N, Adachi T, Kinoshita T,

- Tsushita K, Miyamura K, Naoe T, Sugiura I. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation. *Am J Hematol* 2009; **84**: 283-6.
86. Kamei M, Nannya Y, Torikai H, Kawase T, Taura K, Inamoto Y, Takahashi T, Yazaki M, Morishima S, Tsujimura K, Miyamura K, Ito T, Togari H, Riddell SR, Kodera Y, Morishima Y, Kuzushima K, Ogawa S, Akatsuka Y. HapMap scanning of novel human minor histocompatibility antigens. *Blood* 2009; **113**: 5041-8.
87. Kuwatsuka Y, Miyamura K, Suzuki R, Kasai M, Maruta A, Ogawa H, Tanosaki R, Takahashi S, Koda K, Yago K, Atsuta Y, Yoshida T, Sakamaki H, Kodera Y. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. *Blood* 2009; **113**: 2096-103.
88. Nakashima T, Miyamura K, Sakai T, Kawai T. Photo-, solvent-, and ion-controlled multichromism of imidazolium-substituted diarylethenes. *Chemistry* 2009; **15**: 1977-84.
89. Narimatsu H, Miyamura K, Iida H, Hamaguchi M, Uchida T, Morishita Y. Early central nervous complications after umbilical cord blood transplantation for adults. *Biol Blood Marrow Transplant* 2009; **15**: 92-100.
90. Nishiwaki S, Miyamura K, Seto A, Watanabe K, Yanagisawa M, Imahashi N, Shimba M, Yasuda T, Kuwatsuka Y, Oba T, Terakura S, Kodera Y. Impact of the basal metabolic ratio in predicting early deaths after allogeneic stem cell transplantation. *Am J Hematol* 2009; **84**: 608-11.
91. Nishiwaki S, Terakura S, Ito M, Goto T, Seto A, Watanabe K, Yanagisawa M, Imahashi N, Tsukamoto S, Shimba M, Ozawa Y, Miyamura K. Impact of macrophage infiltration of skin lesions on survival after allogeneic stem cell transplantation: a clue to refractory graft-versus-host disease. *Blood* 2009; **114**: 3113-6.
92. Teshima T, Nagafuji K, Henzan H, Miyamura K, Takase K, Hidaka M, Miyamoto T, Takenaka K, Akashi K, Harada M. Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. *Int J Hematol* 2009; **90**: 253-60.

93. Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, Ohyashiki K, Nishimura M, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Hughes T, Branford S, Okamoto S, Ishikawa J, Okada M, Usui N, Tanii H, Amagasaki T, Natori H, Naoe T. A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph⁺ CML or relapsed/refractory Ph⁺ ALL. *Int J Hematol* 2009; **89**: 679-88.
94. Yagasaki F, Niwa T, Abe A, Ishikawa M, Kato C, Ogura K, Sasaki H, Kyo T, Jinnai I, Bessyo M, Miyamura K. [Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR]. *Rinsho Ketsueki* 2009; **50**: 481-7.
95. Imahashi N, Inamoto Y, Seto A, Watanabe K, Nishiwaki S, Yanagisawa M, Shinba M, Yasuda T, Kuwatsuka Y, Atsuta Y, Kodera Y, Miyamura K. Impact on relapse of corticosteroid therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. *Clin Transplant* 2010; **24**: 772-7.
96. Imahashi N, Miyamura K, Seto A, Watanabe K, Yanagisawa M, Nishiwaki S, Shinba M, Yasuda T, Kuwatsuka Y, Terakura S, Kodera Y. Eosinophilia predicts better overall survival after acute graft-versus-host-disease. *Bone Marrow Transplant* 2010; **45**: 371-7.
97. Imahashi N, Ohashi H, Arita K, Kitamura K, Takahashi T, Ozawa Y, Miyamura K. Acute lymphoblastic leukemia of male-recipient origin demonstrating female karyotype after cord blood transplantation. *J Clin Oncol* 2010; **28**: e750-2.
98. Inamoto Y, Murata M, Katsumi A, Kuwatsuka Y, Tsujimura A, Ishikawa Y, Sugimoto K, Onizuka M, Terakura S, Nishida T, Kanie T, Taji H, Iida H, Suzuki R, Abe A, Kiyoi H, Matsushita T, Miyamura K, Kodera Y, Naoe T. Donor single nucleotide polymorphism in the CCR9 gene affects the incidence of skin GVHD. *Bone Marrow Transplant* 2010; **45**: 363-9.
99. Ishikawa Y, Kiyoi H, Watanabe K, Miyamura K, Nakano Y, Kitamura K, Kohno A, Sugiura I, Yokozawa T, Hanamura A, Yamamoto K, Iida H, Emi N, Suzuki R, Ohnishi K, Naoe T. Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. *Cancer Sci* 2010; **101**: 2186-92.

100. Nishiwaki S, Inamoto Y, Sakamaki H, Kurokawa M, Iida H, Ogawa H, Fukuda T, Ozawa Y, Kobayashi N, Kasai M, Mori T, Iwato K, Yoshida T, Onizuka M, Kawa K, Morishima Y, Suzuki R, Atsuta Y, Miyamura K. Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. *Blood* 2010; **116**: 4368-75.
101. Nishiwaki S, Miyamura K, Kato C, Terakura S, Ohashi K, Sakamaki H, Nakao S, Harigae H, Kodera Y. Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia. *Anticancer Res* 2010; **30**: 2415-8.
102. Nishiwaki S, Terakura S, Yasuda T, Imahashi N, Sao H, Iida H, Kamiya Y, Niimi K, Morishita Y, Kohno A, Yokozawa T, Ohashi H, Sawa M, Kodera Y, Miyamura K. Outcome of allogeneic bone marrow transplantation from unrelated donors for adult Philadelphia chromosome-negative acute lymphocytic leukemia in first complete-remission. *Int J Hematol* 2010; **91**: 419-25.
103. Espinoza JL, Takami A, Nakata K, Onizuka M, Kawase T, Akiyama H, Miyamura K, Morishima Y, Fukuda T, Kodera Y, Nakao S. A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. *PLoS One* 2011; **6**: e26229.
104. Espinoza JL, Takami A, Onizuka M, Kawase T, Sao H, Akiyama H, Miyamura K, Okamoto S, Inoue M, Ohtake S, Fukuda T, Morishima Y, Kodera Y, Nakao S. A single nucleotide polymorphism of IL-17 gene in the recipient is associated with acute GVHD after HLA-matched unrelated BMT. *Bone Marrow Transplant* 2011; **46**: 1455-63.
105. Espinoza LJ, Takami A, Nakata K, Yamada K, Onizuka M, Kawase T, Sao H, Akiyama H, Miyamura K, Okamoto S, Inoue M, Fukuda T, Morishima Y, Kodera Y, Nakao S. Genetic variants of human granzyme B predict transplant outcomes after HLA matched unrelated bone marrow transplantation for myeloid malignancies. *PLoS One* 2011; **6**: e23827.
106. Hirosawa T, Torikai H, Yanagisawa M, Kamei M, Imahashi N, Demachi-Okamura A, Tanimoto M, Shiraishi K, Ito M, Miyamura K, Shibata K, Kikkawa F, Morishima Y,

- Takahashi T, Emi N, Kuzushima K, Akatsuka Y. Mismatched human leukocyte antigen class II-restricted CD8(+) cytotoxic T cells may mediate selective graft-versus-leukemia effects following allogeneic hematopoietic cell transplantation. *Cancer Sci* 2011; **102**: 1281-6.
107. Inamoto Y, Miyamura K, Okamoto S, Akiyama H, Iida H, Eto T, Morishima Y, Kawa K, Kikuchi A, Nagatoshi Y, Tanaka J, Ashida T, Hirokawa M, Tsuchida M, Mori S. Disease stage stratified effects of cell dose in unrelated BMT for hematological malignancies: a report from Japan Marrow Donor Program. *Bone Marrow Transplant* 2011; **46**: 1192-202.
108. Kroger N, Miyamura K, Bishop MR. Minimal residual disease following allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2011; **17**: S94-100.
109. Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. *Blood* 2011; **117**: 2366-72.
110. Murase M, Nishida T, Onizuka M, Inamoto Y, Sugimoto K, Imahashi N, Murata M, Miyamura K, Kodera Y, Inoko H, Naoe T. Cytotoxic T-lymphocyte antigen 4 haplotype correlates with relapse and survival after allogeneic hematopoietic SCT. *Bone Marrow Transplant* 2011; **46**: 1444-9.
111. Nishiwaki S, Inamoto Y, Imamura M, Tsurumi H, Hatanaka K, Kawa K, Suzuki R, Miyamura K. Reduced-intensity versus conventional myeloablative conditioning for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in complete remission. *Blood* 2011; **117**: 3698-9.
112. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with

- previously untreated acute myeloid leukemia: the JALSG AML201 Study. *Blood* 2011; **117**: 2358-65.
113. Takami A, Espinoza JL, Onizuka M, Ishiyama K, Kawase T, Kanda Y, Sao H, Akiyama H, Miyamura K, Okamoto S, Inoue M, Ohtake S, Fukuda T, Morishima Y, Kodera Y, Nakao S. A single-nucleotide polymorphism of the Fcγ receptor type IIIA gene in the recipient predicts transplant outcomes after HLA fully matched unrelated BMT for myeloid malignancies. *Bone Marrow Transplant* 2011; **46**: 238-43.
114. Terakura S, Atsuta Y, Sawa M, Ohashi H, Kato T, Nishiwaki S, Imahashi N, Yasuda T, Murata M, Miyamura K, Suzuki R, Naoe T, Ito T, Morishita Y. A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies. *Ann Oncol* 2011; **22**: 1865-71.
115. Imahashi N, Inamoto Y, Ito M, Koyama D, Goto T, Onodera K, Seto A, Watanabe K, Imahashi M, Nishiwaki S, Tsukamoto S, Yasuda T, Ozawa Y, Miyamura K. Clinical significance of hemophagocytosis in BM clot sections during the peri-engraftment period following allogeneic hematopoietic SCT. *Bone Marrow Transplant* 2012; **47**: 387-94.
116. Kanda J, Saji H, Fukuda T, Kobayashi T, Miyamura K, Eto T, Kurokawa M, Kanamori H, Mori T, Hidaka M, Iwato K, Yoshida T, Sakamaki H, Tanaka J, Kawa K, Morishima Y, Suzuki R, Atsuta Y, Kanda Y. Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: a nationwide retrospective study. *Blood* 2012; **119**: 2409-16.
117. Minami Y, Abe A, Minami M, Kitamura K, Hiraga J, Mizuno S, Yamamoto K, Sawa M, Inagaki Y, Miyamura K, Naoe T. Retention of CD34(+) CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR-ABL inhibitors. *Leukemia* 2012;
118. Nishiwaki S, Miyamura K. Allogeneic stem cell transplant for adult Philadelphia chromosome-negative acute lymphoblastic leukemia. *Leuk Lymphoma* 2012; **53**: 550-6.

119. Nishiwaki S, Nakayama T, Murata M, Nishida T, Sugimoto K, Saito S, Kato T, Mizuno H, Imahashi N, Seto A, Ozawa Y, Goto T, Koyama D, Yokohata E, Kubota N, Kamoshita S, Miyamura K, Matsumoto K, Ito M, Naoe T. Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic stem cell transplantation: macrophage-targeted steroid therapy. *Int J Hematol* 2012; **95**: 428-33.
120. Ohnishi K, Nakaseko C, Takeuchi J, Fujisawa S, Nagai T, Yamazaki H, Tauchi T, Imai K, Mori N, Yagasaki F, Maeda Y, Usui N, Miyazaki Y, Miyamura K, Kiyoi H, Ohtake S, Naoe T. Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. *Cancer Sci* 2012;
121. Usuki K, Tojo A, Maeda Y, Kobayashi Y, Matsuda A, Ohyashiki K, Nakaseko C, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Okamoto S, Oritani K, Okada M, Usui N, Nagai T, Amagasaki T, Wanajo A, Naoe T. Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study. *Int J Hematol* 2012; **95**: 409-19.
122. Watanabe K, Minami Y, Ozawa Y, Miyamura K, Naoe T. T315I Mutation in Ph-positive Acute Lymphoblastic Leukemia is Associated with a Highly Aggressive Disease Phenotype: Three Case Reports. *Anticancer Res* 2012; **32**: 1779-83.
123. Yamada-Fujiwara M, Miyamura K, Fujiwara T, Tohmiya Y, Endo K, Onishi Y, Ishizawa K, Kameoka J, Ito M, Harigae H. Diagnosis of Intestinal Graft-versus-Host Disease and Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation. *Tohoku J Exp Med* 2012; **227**: 31-7.
124. Yanada M, Ohtake S, Miyawaki S, Sakamaki H, Sakura T, Maeda T, et al. The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studies. *Cancer*. 2013 Sep 15;**119**(18):3326-33.
125. Tanaka J, Morishima Y, Takahashi Y, Yabe T, Oba K, Takahashi S, et al. Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission. *Blood cancer journal*. 2013;3:e164.

126. Tanaka J, Kanamori H, Nishiwaki S, Ohashi K, Taniguchi S, Eto T, et al. Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). *Bone marrow transplantation*. 2013 Nov;**48**(11):1389-94.
127. Nishiwaki S, Miyamura K, Ohashi K, Kurokawa M, Taniguchi S, Fukuda T, et al. Impact of a donor source on adult Philadelphia chromosome-negative acute lymphoblastic leukemia: a retrospective analysis from the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2013 Jun;**24**(6):1594-602.
128. Nakata K, Takami A, Espinoza JL, Matsuo K, Morishima Y, Onizuka M, et al. The recipient CXCL10 + 1642C>G variation predicts survival outcomes after HLA fully matched unrelated bone marrow transplantation. *Clinical immunology*. 2013 Feb;**146**(2):104-11.
129. Nakasone H, Onizuka M, Suzuki N, Fujii N, Taniguchi S, Kakihana K, et al. Pre-transplant risk factors for cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia after hematopoietic cell transplantation. *Bone marrow transplantation*. 2013 Oct;**48**(10):1317-23.
130. Nakasone H, Kurosawa S, Yakushijin K, Taniguchi S, Murata M, Ikegame K, et al. Impact of hepatitis C virus infection on clinical outcome in recipients after allogeneic hematopoietic cell transplantation. *American journal of hematology*. 2013 Jun;**88**(6):477-84.
131. Muroi K, Miyamura K, Ohashi K, Murata M, Eto T, Kobayashi N, et al. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study. *International journal of hematology*. 2013 Aug;**98**(2):206-13.
132. Miyamura K. [Increasing options of stem cell sources]. [Rinsho ketsueki] *The Japanese journal of clinical hematology*. 2013 Feb;**54**(2):145-55.
133. Kurosawa S, Yakushijin K, Yamaguchi T, Atsuta Y, Nagamura-Inoue T, Akiyama H, et al. Changes in incidence and causes of non-relapse mortality after allogeneic

- hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry. *Bone marrow transplantation*. 2013 Apr;**48**(4):529-36.
134. Kurosawa S, Yakushijin K, Yamaguchi T, Atsuta Y, Nagamura-Inoue T, Akiyama H, et al. Recent decrease in non-relapse mortality due to GVHD and infection after allogeneic hematopoietic cell transplantation in non-remission acute leukemia. *Bone marrow transplantation*. 2013 Sep;**48**(9):1198-204.
135. Kodera Y, Yamamoto K, Harada M, Morishima Y, Dohy H, Asano S, et al. PBSC collection from family donors in Japan: a prospective survey. *Bone marrow transplantation*. 2014 Feb;**49**(2):195-200.
136. Kanda Y, Oshima K, Kako S, Fukuda T, Uchida N, Miyamura K, et al. In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation. *American journal of hematology*. 2013 Apr;**88**(4):294-300.
137. Kanda Y, Kanda J, Atsuta Y, Maeda Y, Ichinohe T, Ohashi K, et al. Impact of a single human leucocyte antigen (HLA) allele mismatch on the outcome of unrelated bone marrow transplantation over two time periods. A retrospective analysis of 3003 patients from the HLA Working Group of the Japan Society for Blood and Marrow Transplantation. *British journal of haematology*. 2013 May;**161**(4):566-77.
138. Kanda J, Nakasone H, Atsuta Y, Toubai T, Yokoyama H, Fukuda T, et al. Risk factors and organ involvement of chronic GVHD in Japan. *Bone marrow transplantation*. 2014 Feb;**49**(2):228-35.
139. Kanda J, Ichinohe T, Kato S, Uchida N, Terakura S, Fukuda T, et al. Unrelated cord blood transplantation vs related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction. *Leukemia*. 2013 Feb;**27**(2):286-94.
140. Kanamori T, Kayukawa S, Kikuchi T, Totani H, Miyamura K, Ito M, et al. [Case report: a case of donor cell-derived diffuse large B-cell lymphoma after 24-year remission of acute myeloid leukemia followed by successful allogeneic bone marrow transplantation]. *Nihon Naika Gakkai zasshi The Journal of the Japanese Society of Internal Medicine*. 2013 Mar 10;**102**(3):721-3.

141. Kako S, Morita S, Sakamaki H, Iida H, Kurokawa M, Miyamura K, et al. The role of HLA-matched unrelated transplantation in adult patients with Ph chromosome-negative ALL in first remission. A decision analysis. *Bone marrow transplantation*. 2013 Aug;**48**(8):1077-83.
142. Imahashi N, Suzuki R, Fukuda T, Kakihana K, Kanamori H, Eto T, et al. Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR. *Bone marrow transplantation*. 2013 Jan;**48**(1):56-62.
143. Goto T, Ikuta K, Inamoto Y, Kamoshita S, Yokohata E, Koyama D, et al. Hyperferritinemia after adult allogeneic hematopoietic cell transplantation: quantification of iron burden by determining non-transferrin-bound iron. *International journal of hematology*. 2013 Jan;**97**(1):125-34.
144. Espinoza JL, Takami A, Onizuka M, Morishima Y, Fukuda T, Kodera Y, et al. Recipient PTPN22 -1123 C/C genotype predicts acute graft-versus-host disease after HLA fully matched unrelated bone marrow transplantation for hematologic malignancies. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2013 Feb;**19**(2):240-6.
145. Atsuta Y, Suzuki R, Yamashita T, Fukuda T, Miyamura K, Taniguchi S, et al. Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2014 Feb;**25**(2):435-41.
146. Fuji S, Kanda J, Kato S, Ikegame K, Morishima S, Miyamoto T, Miyamura K, et al. Impact of HLA allele mismatch on the clinical outcome in serologically matched related hematopoietic SCT. *Bone marrow transplantation*. 2014 Sep;**49**(9):1187-92.
147. Fuji S, Takano K, Mori T, Eto T, Taniguchi S, Ohashi K, Miyamura K, et al. Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT. *Bone marrow transplantation*. 2014 Dec;**49**(12):1505-12.
148. Kanda J, Fuji S, Kato S, Takami A, Tanaka J, Miyamura K, et al. Decision analysis for donor selection in stem cell transplantation-HLA-8/8 allele-matched unrelated donor vs HLA-1 AG mismatched related donor. *Blood cancer journal*. 2014;**4**:e263.

149. Kanda J, Ichinohe T, Fuji S, Maeda Y, Ohashi K, Fukuda T, Miyamura K, et al. Impact of HLA mismatch direction on the outcome of unrelated bone marrow transplantation: a retrospective analysis from the Japan Society for Hematopoietic Cell Transplantation. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2015 Feb;**21**(2):305-11.
150. Kanda Y, Kanda J, Atsuta Y, Fuji S, Maeda Y, Ichinohe T, Miyamura K, et al. Changes in the clinical impact of high-risk human leukocyte antigen allele mismatch combinations on the outcome of unrelated bone marrow transplantation. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2014 Apr;**20**(4):526-35.
151. Kato H, Kawase T, Kako S, Mizuta S, Kurokawa M, Mori T, Miyamura K, et al. Analysis of outcomes following autologous stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia during first complete remission. *Haematologica*. 2014 Nov;**99**(11):e228-30.
152. Kodera Y, Yamamoto K, Harada M, Morishima Y, Dohy H, Asano S, Miyamura K, et al. PBSC collection from family donors in Japan: a prospective survey. *Bone marrow transplantation*. 2014 Feb;**49**(2):195-200.
153. Miyamura K, Okamoto S, Usui N, Hino M, Akashi K, Nakaseko T, et al. Evaluation of clinical performance of the major BCR-ABL mRNA detection kit which enables conversion to international standard scale using the reference material calibrator. [Rinsho ketsueki] *The Japanese journal of clinical hematology*. 2014 May;**55**(5):534-40.
154. Mizuta S, Matsuo K, Nishiwaki S, Imai K, Kanamori H, Ohashi K, Miyamura K, et al. Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia. *Blood*. 2014 Apr 10;**123**(15):2325-32.
155. Morishima S, Nakamura S, Yamamoto K, Miyauchi H, Kagami Y, Kinoshita T, Miyamura K, et al. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma. *Leukemia & lymphoma*. 2014 Aug **13**:1-7.

156. Nishiwaki S, Nakayama T, Murata M, Nishida T, Terakura S, Saito S, Miyamura K, et al. Dexamethasone palmitate ameliorates macrophages-rich graft-versus-host disease by inhibiting macrophage functions. *PLoS one*. 2014;**9**(5):e96252.
157. Morishima Y, Kashiwase K, Matsuo K, Azuma F, Morishima S, Onizuka M, Miyamura K, et al. Biological significance of HLA locus matching in unrelated donor bone marrow transplantation. *Blood*. 2015 Feb 12;**125**(7):1189-97.
158. Imahashi N, Ohashi H, Terakura S, Miyao K, Sakemura R, Kato T, Miyamura K, et al. Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse. *Annals of hematology*. 2015 Feb 15.
159. Kanda J, Ichinohe T, Fuji S, Maeda Y, Ohashi K, Fukuda T, Miyamura K, et al. Impact of HLA mismatch direction on the outcome of unrelated bone marrow transplantation: a retrospective analysis from the Japan Society for Hematopoietic Cell Transplantation. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2015 Feb;**21**(2):305-11.
160. Tanaka M, Miyamura K, Terakura S, Imai K, Uchida N, Ago H, et al. Comparison of cord blood transplantation with unrelated bone marrow transplantation in patients older than fifty years. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2015 Mar;**21**(3):517-25.
161. Nakasone H, Fukuda T, Kanda J, Mori T, Yano S, Kobayashi T, Miyamura K, et al. Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation. *Bone marrow transplantation*. 2015 Apr;**50**(4):559-65.
162. Morishima S, Nakamura S, Yamamoto K, Miyauchi H, Kagami Y, Kinoshita T, Miyamura K, et al. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma. *Leukemia & lymphoma*. 2015 Apr;**56**(4):1072-8.
163. Fuji S, Kanda J, Kato S, Ikegame K, Morishima S, Miyamoto T, Miyamura K, et al. A single high-resolution HLA mismatch has a similar adverse impact on the outcome of related hematopoietic stem cell transplantation as a single low-resolution HLA mismatch. *American journal of hematology*. 2015 Jul;**90**(7):618-23.

164. Konuma T, Takahashi S, Uchida N, Kuwatsuka Y, Yamasaki S, Aoki J, Miyamura K, et al. Effect of Granulocyte Colony-Stimulating Factor-Combined Conditioning in Cord Blood Transplantation for Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia: A Retrospective Study in Japan. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2015 Sep;**21**(9):1632-40.
165. Hanajiri R, Murata M, Sugimoto K, Murase M, Sakemura R, Goto T, Miyamura K, et al. Integration of humoral and cellular HLA-specific immune responses in cord blood allograft rejection. *Bone marrow transplantation*. 2015 Sep;**50**(9):1187-94.
166. Terakura S, Atsuta Y, Tsukada N, Kobayashi T, Tanaka M, Kanda J, Miyamura K, et al. Comparison of Outcomes of 8/8 and 7/8 Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Cord Blood Transplantation in Adults with Acute Leukemia. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2015 Oct 22.
167. Nomoto H, Takami A, Espinoza JL, Matsuo K, Mizuno S, Onizuka M, Miyamura K, et al. A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation. *International journal of hematology*. 2015 Oct;**102**(4):460-70.
168. Nomoto H, Takami A, Espinoza JL, Matsuo K, Mizuno S, Onizuka M, Miyamura K, et al. Erratum to: A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation. *International journal of hematology*. 2015 Oct;**102**(4):507-8.
169. Mori J, Ishiyama K, Yamaguchi T, Tanaka J, Uchida N, Kobayashi T, Miyamura K, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with biphenotypic acute leukemia. *Annals of hematology*. 2015 Oct 26.
170. Miyao K, Sawa M, Kuwatsuka Y, Ozawa Y, Kato T, Kohno A, Miyamura K, et al. Influence of melphalan plus fludarabine-conditioning regimen in elderly patients aged 55 years with hematological malignancies. *Bone marrow transplantation*. 2015 Oct 5.
171. Miura H, Kawamura Y, Kudo K, Ihira M, Ohye T, Kurahashi H, Miyamura K, et al. Virological analysis of inherited chromosomally integrated human herpesvirus-6 in

three hematopoietic stem cell transplant patients. *Transplant infectious disease : an official journal of the Transplantation Society*. 2015 Oct;**17**(5):728-31.

172. Arima N, Nakamura F, Yabe T, Tanaka J, Fuji S, Ohashi K, Miyamura K, et al. Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia: A Japanese National Registry Study. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2015 Oct 9.
173. Yakushijin K, Atsuta Y, Doki N, Yokota A, Kanamori H, Miyamoto T, Miyamura K, et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes. *Bone marrow transplantation*. 2015 Nov 23.
174. Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Miyamura K, et al. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2015 Nov;**21**(11):2008-16.
175. Muroi K, Miyamura K, Okada M, Yamashita T, Murata M, Ishikawa T, et al. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. *International journal of hematology*. 2015 Nov 25.
176. Miyamura K. Insurance approval of mesenchymal stem cell for acute GVHD in Japan: need of follow up for some remaining concerns. *International journal of hematology*. 2016 Feb;**103**(2):155-64.
177. Sakai R, Taguri M, Oshima K, Mori T, Ago H, Adachi S, Miyamura K, et al. A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey. *International journal of hematology*. 2016 Mar;**103**(3):322-33.
178. Kanda J, Brazauskas R, Hu ZH, Kuwatsuka Y, Nagafuji K, Kanamori H, Miyamura

- K, et al. Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2016 Apr;**22**(4):744-51..
179. Kumar R, Kimura F, Ahn KW, Hu ZH, Kuwatsuka Y, Klein JP, Miyamura K, et al. Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2016 May;**22**(5):932-40.
180. Konuma T, Tsukada N, Kanda J, Uchida N, Ohno Y, Miyakoshi S, Miyamura K, et al. Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older. *American journal of hematology*. 2016 May;**91**(5):E284-92.
181. Uchino K, Mizuno S, Mizutani M, Horio T, Hanamura I, Espinoza JL, Miyamura K, et al. Toll-like receptor 1 variation increases the risk of transplant-related mortality in hematologic malignancies. *Transplant immunology*. 2016 Jun 28.
182. Kuwatsuka Y, Kanda J, Yamazaki H, Mori T, Miyamura K, Kako S, et al. A Comparison of Outcomes for Cord Blood Transplant and Unrelated Bone Marrow Transplant in Adult Aplastic Anemia. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2016 Jul 8.
183. Kawashima N, Inamoto Y, Sato T, Nakashima M, Kagaya Y, Watakabe K, Miyamura K, et al. Long-term outcomes of allogeneic hematopoietic cell transplantation with intensified myeloablative conditioning for refractory myeloid malignancy. *Bone marrow transplantation*. 2016 Jun;**51**(6):869-71.
184. Ishiyama K, Yamaguchi T, Eto T, Ohashi K, Uchida N, Kanamori H, Miyamura K, et al. Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT. *Leukemia research*. 2016 Aug;**47**:47-53.
185. Uchino K, Mizuno S, Mizutani M, Horio T, Hanamura I, Espinoza JL, Miyamura K, et al. Toll-like receptor 1 variation increases the risk of transplant-related mortality in hematologic malignancies. *Transpl Immunol*. 2016 Sep;**38**:60-6.

186. Yanada M, Kanda J, Ohtake S, Fukuda T, Sakamaki H, Miyamura K, et al. Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission. *Eur J Haematol*. 2016 Sep;97(3):278-87.
187. Kuwatsuka Y, Kanda J, Yamazaki H, Mori T, Miyamura K, Kako S, et al. A Comparison of Outcomes for Cord Blood Transplantation and Unrelated Bone Marrow Transplantation in Adult Aplastic Anemia. *Biol Blood Marrow Transplant*. 2016 Oct;22(10):1836-43.
188. Miyamura K, Miyamoto T, Tanimoto M, Yamamoto K, Kimura S, Kawaguchi T, et al. Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy. *Leuk Res*. 2016 Dec;51:11-8.
189. Sakaguchi H, Watanabe N, Matsumoto K, Yabe H, Kato S, Ogawa A, Miyamura K, et al. Comparison of Donor Sources in Hematopoietic Stem Cell Transplantation for Childhood Acute Leukemia: A Nationwide Retrospective Study. *Biol Blood Marrow Transplant*. 2016 Dec;22(12):2226-34.
190. Koyama D, Ito M, Yokohata E, Watakabe K, Onodera K, Goto T, Miyamura K, et al. Autoimmune-like hepatitis after allogeneic hematopoietic stem cell transplantation: humoral hepatic GvHD. *Bone Marrow Transplant*. 2017 Jan;52(1):151-3.
191. Shigematsu A, Kako S, Mitsuhashi K, Iwato K, Uchida N, Kanda Y, Miyamura K, et al. Allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia who had central nervous system involvement: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation. *Int J Hematol*. 2017 Jun;105(6):805-11.
192. Mukoyama N, Nakashima M, Miyamura K, Yoshimi A, Noda Y, Mori K. Retrospective survey and evaluation of first-line antibiotics for chemotherapy-induced febrile neutropenia in patients with acute myeloid leukemia. *Nagoya J Med Sci*. 2017 Feb;79(1):17-26.
193. Nakasone H, Fuji S, Yakushijin K, Onizuka M, Shinohara A, Ohashi K, Miyamura K, et al. Impact of total body irradiation on successful neutrophil engraftment in

- unrelated bone marrow or cord blood transplantation. *Am J Hematol.* 2017 Feb;92(2):171-8.
194. Takahashi N, Nakaseko C, Kobayashi Y, Miyamura K, Ono C, Koide Y, et al. Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment. *Int J Hematol.* 2017 Apr 13.
195. Tojo A, Kyo T, Yamamoto K, Nakamae H, Takahashi N, Kobayashi Y, Miyamura K, et al. Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study. *Int J Hematol.* 2017 Apr 25
196. Yokohata E, Kuwatsuka Y, Ohashi H, Terakura S, Kawashima N, Seto A, Miyamura K, et al. Impact of T-cell chimerism on relapse after cord blood transplantation for hematological malignancies: Nagoya Blood and Marrow Transplantation Group study. *Bone Marrow Transplant.* 2017 Apr;52(4):612-4.
197. Horio T, Mizuno S, Uchino K, Mizutani M, Hanamura I, Espinoza JL, Miyamura K, et al. The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation. *Transpl Immunol.* 2017 Jun;42:34-9.
198. Kurosawa S, Oshima K, Yamaguchi T, Yanagisawa A, Fukuda T, Kanamori H, Miyamura K, et al. Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease. *Biol Blood Marrow Transplant.* 2017 Jun 29.
199. Uchino K, Mizuno S, Sato-Otsubo A, Nannya Y, Mizutani M, Horio T, Miyamura K, et al. Toll-like receptor genetic variations in bone marrow transplantation. *Oncotarget.* 2017 Jul 11;8(28):45670-86.
200. Kawashima N, Terakura S, Nishiwaki S, Koyama D, Ozawa Y, Ito M, Miyamura K, et al. Increase of bone marrow macrophages and CD8+ T lymphocytes predict graft failure after allogeneic bone marrow or cord blood transplantation. *Bone Marrow Transplant.* 2017 Aug;52(8):1164-70.
201. Yuda J, Miyamoto T, Odawara J, Ohkawa Y, Semba Y, Hayashi M, Miyamura K, et al. Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response. *Cancer Sci.* 2017 Aug 12.

